Safety and tolerablilty of HPV mRNA vaccine in HPV-driven squamous cell carcinoma.

Trial Profile

Safety and tolerablilty of HPV mRNA vaccine in HPV-driven squamous cell carcinoma.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs RBLO15.1(LIP)/RBLO16.1(LIP) (Primary)
  • Indications Cervical cancer; Head and neck cancer; Penile cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms HARE-40
  • Most Recent Events

    • 27 Sep 2017 New source identified and integrated European Clinical Trials Database (EudraCT2014-002061-30).
    • 26 Sep 2017 New trial record
    • 09 Sep 2017 Results assessing safety and tolerablilty of HPV mRNA vaccine in HPV16 positive, head and neck, cervical, anogenital and penile carcinoma patients with recurrent disease, were presented at the 3rd CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top